Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

2022505 citationsJournal Articlehybrid Open Access

Authors

Exelixis and Ipsen.

Good health and well-being

Published in: The Lancet Oncology

Volume 23, Issue 8, pp. 995-1008

Field-Weighted Citation Impact: 104.96